Clinical Trials
2,479 trialsStudy of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
University of Florida
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Pfizer
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
University of Arizona
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune LLC
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
National Institutes of Health Clinical Center (CC)
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
First Hospital of China Medical University
IO-MARC
Universitaire Ziekenhuizen KU Leuven
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
Huahui Health
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
M.D. Anderson Cancer Center
Intravital Microscopy in Human Solid Tumors
Mayo Clinic
DYNAMIC
Asan Medical Center
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
ROWAN
Boston Scientific Corporation
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
University of Southern California
Kirros
Genentech, Inc.
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
HERO
Université de Montréal
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
Henan Cancer Hospital
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
National Cancer Institute (NCI)
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
National Cancer Institute (NCI)
Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
CONV3RSION
First Hospital of China Medical University
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
STELLAR-002
Exelixis
REVIVE
Asan Medical Center
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
City of Hope Medical Center
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
M.D. Anderson Cancer Center
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
M.D. Anderson Cancer Center
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
M.D. Anderson Cancer Center
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
ATHENA
AstraZeneca
CCGLC-011
Tongji Hospital
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
INDIGO
Boston Scientific Corporation
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute